Search
Insilico Medicine Publishes in Nature Sub-journal: AI Drives Progress in Innovative Immunotherapy
2025-05-29 /
Read about 0 minute
Author：小编
Insilico Medicine has triumphantly developed ISM5939, a highly targeted oral ENPP1 inhibitor, leveraging advanced AI technology. This novel drug significantly enhances the effectiveness of tumor immunotherapy by modulating the STING pathway. Research highlights that ENPP1 is overexpressed in various solid tumors, making ISM5939 a promising candidate for use in combination with immune checkpoint inhibitors and chemotherapy drugs. This combination not only amplifies anti-tumor immune responses but also demonstrates exceptional safety profiles. In 2023, ISM5939 was recognized as a drug candidate, and in 2024, it secured FDA approval for clinical trials, representing a groundbreaking achievement for AI in the realm of drug development.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
